Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial
Sanjay Ramakrishnan(The University of Western Australia), Mona Bafadhel(National Institute for Health and Care Excellence), J. Mark Melhorn(University of Oxford), Richard Russell(Southern Health NHS Foundation Trust), Christine Mwasuku(National Institute for Health and Care Research), Mahdi Mahdi(National Institute for Health and Care Research), Ian Pavord(University of Oxford), Stefan Peterson(WeMind), Karolina Krassowska(National Institute for Health and Care Research), Thomas Bengtsson(WeMind), Hafiz Taha Mahmood(The University of Western Australia), Laura Bermejo-Sanchez(University of Oxford), Imran Howell(Institute of Cancer Research)
Cited by 98
Related Papers
Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study
|The Lancet Respiratory Medicine|2015|584
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts
|New England Journal of Medicine|2023|452
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
|The Lancet Respiratory Medicine|2021|434
Benralizumab for the Prevention of COPD Exacerbations
|New England Journal of Medicine|2019|329